Directorate Change

11^th Apr 2016

EKF Diagnostics Holdings plc (AIM: EKF), the point-of-care business, announces that Ron Zwanziger has resigned as a non-executive director with immediate effect.

EKF Diagnostics Holdings plc Julian Baines, CEO	00 44 29 2071 0570 00 44 7788 420 859
Panmure Gordon (UK) Limited Robert Naylor Paul Fincham	00 44 20 7886 2500
Walbrook PR Limited Paul McManus Lianne Cawthorne	00 44 20 7933 8780 or ekf@walbrookpr.com 00 44 7980 541 893 00 44 7584 391 303

Back to Listing

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

EKF opens larger facility to increase production of key component for COVID-19 testing regime

EKF’s new facilities in Llandough, Cardiff, for manufacture of PrimeStore^® MTM viral transport media, enabling pathogenic samples to be collected and transported safely and easily in compliance with UN3373 packaging regulations.

EKF fly the extra mile over Christmas

New COVID-SeroKlir SARS-CoV-2 IgG antibody test kit is one of first to detect both the presence and precise levels of COVID-19 neutralizing antibodies

EKF introduces accurate quantitative COVID-19 antibody test kit

New COVID-SeroKlir SARS-CoV-2 IgG antibody test kit is one of first to detect both the presence and precise levels of COVID-19 neutralizing antibodies

EKF launches PrimeStore® MTM pathogenic sample collection and transportation kit

New sample collection kit enables convenient and safe collection, transportation and handling of pathogenic samples including COVID-19 and influenza.

PrimeStore® MTM successfully evaluated by Public Health England for SARS-CoV-2 inactivation

Patented transport media manufactured by EKF Diagnostics can help to increase COVID-19 testing capacity